# Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

> **NCT05024773** · PHASE3 · RECRUITING · sponsor: **Fidia Farmaceutici s.p.a.** · enrollment: 112 (estimated)

## Conditions studied

- Bladder Carcinoma in Situ (CIS)

## Interventions

- **DRUG:** ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)

## Key facts

- **NCT ID:** NCT05024773
- **Lead sponsor:** Fidia Farmaceutici s.p.a.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-29
- **Primary completion:** 2026-03
- **Final completion:** 2027-11
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024773, "Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05024773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*